4.5 Review

Antimicrobial Stewardship from Policy to Practice: Experiences from UK Antimicrobial Pharmacists

期刊

INFECTIOUS DISEASES AND THERAPY
卷 4, 期 -, 页码 51-64

出版社

SPRINGER LONDON LTD
DOI: 10.1007/s40121-015-0080-z

关键词

Antibiotic; Antimicrobial stewardship; Healthcare-associated infections; Pharmacy; Resistance

资金

  1. Eumedica Pharmaceuticals
  2. Astellas Pharmaceuticals
  3. Sanofi
  4. Baxter
  5. Clinigen
  6. Cubist
  7. Eumedica
  8. ICNet
  9. Pfizer
  10. Merck Sharpe Dome
  11. Astellas Pharmaceuticals B. Braun
  12. Gilead
  13. Cubist/Merck
  14. UKCPA
  15. AstraZeneca
  16. Basilea/Quintiles
  17. Bayer
  18. Cubist/MSD
  19. Roche
  20. ECDC
  21. BSAC

向作者/读者索取更多资源

Antimicrobial stewardship in the UK has evolved dramatically in the last 15 years. Factors driving this include initial central funding for specialist pharmacists and mandatory reductions in healthcare-associated infections (particularly Clostridium difficile infection). More recently, the introduction of national stewardship guidelines, and an increased focus on stewardship as part of the UK five-year antimicrobial resistance strategy, have accelerated and embedded developments. Antimicrobial pharmacists have been instrumental in effecting changes at an organizational and national level. This article describes the evolution of the antimicrobial pharmacist role, its impact, the progress toward the actions listed in the five-year resistance strategy, and novel emerging areas in stewardship in the UK.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据